973 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
PFE Pfizer, Inc. $43.01 $252.13B Downtrend
Article Searches
Top Research Reports for Pfizer, Royal Dutch Shell & Celgene http://www.zacks.com/research-daily/370129/top-research-reports-for-pfizer-royal-dutch-shell-celgene?cid=CS-ZC-FT-370129 Apr 03, 2019 - Top Research Reports for Pfizer, Royal Dutch Shell & Celgene
Sangamo Rises on Positive Phase I/II Hemophilia Study Data http://www.zacks.com/stock/news/370133/sangamo-rises-on-positive-phase-i-ii-hemophilia-study-data?cid=CS-ZC-FT-370133 Apr 03, 2019 - Sangamo (SGMO) and partner Pfizer announce encouraging data from a phase I/II study evaluating their gene therapy candidate for treating hemophilia A.
Why the Earnings Surprise Streak Could Continue for Pfizer (PFE) http://www.zacks.com/stock/news/370110/why-the-earnings-surprise-streak-could-continue-for-pfizer-pfe?cid=CS-ZC-FT-370110 Apr 03, 2019 - Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Does Sangamo Have the Best Gene Therapy Program Now? https://www.fool.com/investing/2019/04/03/does-sangamo-have-the-best-gene-therapy-program-no.aspx?source=iedfolrf0000001 Apr 03, 2019 - The grandaddy of gene-editing stocks recently provided an encouraging update, but it isn't the only experimental hemophilia therapy out there.
Spero Gets Fast Track Designation for SPR994, Shares Improve http://www.zacks.com/stock/news/368643/spero-gets-fast-track-designation-for-spr994-shares-improve?cid=CS-ZC-FT-368643 Apr 01, 2019 - Spero???s (SPRO) SPR994 receives Fast Track designation by the FDA for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis.
Sarepta (SRPT) Reports Positive Interim Results for DMD Drug http://www.zacks.com/stock/news/367182/sarepta-srpt-reports-positive-interim-results-for-dmd-drug?cid=CS-ZC-FT-367182 Mar 29, 2019 - Sarepta???s (SRPT) key pipeline candidate leads to statistically significant increase in dystrophin production in ESSENCE study. NDA to be filed mid-2019.
Ascendis Pivotal Growth Hormone Deficiency Study Data Positive http://www.zacks.com/stock/news/364371/ascendis-pivotal-growth-hormone-deficiency-study-data-positive?cid=CS-ZC-FT-364371 Mar 25, 2019 - Ascendis Pharma's (ASND) growth hormone deficiency candidate fares better than Pfizer's Genotropin in improving annual rate for increase in height in children.
Aerie (AERI) Starts Phase II Study on Eye Candidate in Japan http://www.zacks.com/stock/news/363393/aerie-aeri-starts-phase-ii-study-on-eye-candidate-in-japan?cid=CS-ZC-FT-363393 Mar 22, 2019 - Aerie (AERI) begins dosing in a phase II study on netarsudil ophthalmic solution in Japan for curbing high intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Shares Up.
Dow 30 Stock Roundup: AAPL Refreshes Product Lineup, BA Wins $327M Navy Order http://www.zacks.com/stock/news/363011/dow-30-stock-roundup-aapl-refreshes-product-lineup-ba-wins-%24327m-navy-order?cid=CS-ZC-FT-363011 Mar 22, 2019 - The index traversed yet another volatile week but still managed to notch up strong gains.
Biogen’s Big Bet in Alzheimer’s Disease Is a Bust https://www.fool.com/investing/2019/03/21/biogens-big-bet-in-alzheimers-disease-is-a-bust.aspx?source=iedfolrf0000001 Mar 21, 2019 - The big biotech's pivot from multiple sclerosis to Alzheimer's disease was dealt a decisive blow today.

Pages: 12345678910...98

<<<Page 5>